Home › Stocks › Pharma & healthcare stocks › Aurobindo Pharma
Pharma & healthcare stocks Valuation research

Aurobindo Pharma fair value — a US generics giant

Aurobindo supplies more generic prescriptions in the US than most rivals. Constant price pressure on generics shapes how its value is judged.

FairStocks Research
Updated 16 Nov 2026 · 4 min read
| NSE: AUROPHARMA ₹1,823
On this page ▾
  1. The business
  2. What the market assumes
  3. The ten-year record
  4. How it is valued
  5. What decides the value
  6. What could go wrong
  7. The full valuation
  8. Questions
Aurobindo Pharma (AUROPHARMA) fair value — is it overvalued? Price ₹1,823, P/E 26.3, P/B 2.77, ROE —. Based on 10 years of reported financials. FairStocks.
Aurobindo Pharma at a glance. Share price, P/E, P/B and the ten-year revenue trend, from filed accounts. Updated 16 Nov 2026.
In 30 seconds

The market expects Aurobindo Pharma to carry on much as it has.

At today’s share price, buyers are assuming Aurobindo Pharma grows about 5% a year, forever. Over the last ten years it actually grew about 8% a year. The two are close, so the share price does not need the business to improve or to stumble. It needs it to keep doing roughly what it already does.

  • How it is valued: Discounted cash flow.
  • What the price assumes: 5% growth, against 8% the model takes from its own record.
  • Ten-year record: Between FY2018 and FY2026, Aurobindo Pharma's revenue went from ₹16,500 crore to ₹33,653 crore — it compounded at about 9% a year over 8 years.
  • Biggest swing factor: US generic launches. Main risk: FDA inspections.
Price
₹1,823
Market cap
₹1.05L Cr
P/E
26.3
P/B
2.77
See Aurobindo's fair value and the full DCFEvery step of the Aurobindo Pharma working, the scenarios and the report Free during launch →

01From ingredients to a global generics supplier

Aurobindo Pharma, founded in Hyderabad in 1986, started making active ingredients and became one of the largest Indian suppliers of generic medicines to the US by number of approved products.

It also has a sizeable European business and Eugia, its injectables arm, and is building biosimilars and other specialty products.

02What the market is assuming

Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Aurobindo Pharma, next to what the model assumes from the company's own record.

Market expects
5%
growth priced into today's price
Model assumes
8%
growth the model assumes

The further apart these two numbers are, the bigger the bet a buyer at today's price is making.

03Aurobindo Pharma's record, in plain numbers

Between FY2018 and FY2026, Aurobindo Pharma's revenue went from ₹16,500 crore to ₹33,653 crore — it compounded at about 9% a year over 8 years. Net profit grew from ₹2,423 crore to ₹3,503 crore, about 5% a year — slower than revenue, so margins narrowed. In FY2026 it kept 10.4% of revenue as net profit — against a low of 7.8% in FY2023 and a high of 21.5% in FY2021. The latest year added 6.1% to revenue, well behind its own long-run pace. FY2019 is missing from the filed series used here, so that year is left out rather than estimated.

Reading the record. FY2021 profit included a one-time gain from selling Natrol, its US nutritional-supplements business; FY2019 is missing from the filed series.
Revenue₹0.16L → ₹0.34L Cr
1820212223242526
Earnings per share₹41.4 → ₹60.3
1820212223242526
Return on equity33.8% → 9.9%
20212223242526
Debt to equity0.02 → 0.02
23242526

Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.

Revenue and net profit by year (₹ crore)
YearRevenueNet profitMargin
FY201816,5002,42314.7%
FY202023,0982,83012.2%
FY202124,7755,33421.5%
FY202223,4552,64711.3%
FY202324,8551,9287.8%
FY202429,0023,16910.9%
FY202531,7243,48411.0%
FY202633,6533,50310.4%

04How Aurobindo Pharma gets valued — and why

Discounted cash flow

This business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.

05What decides Aurobindo Pharma's value

US generic launches

New products offset price erosion.

Injectables

Eugia adds higher-margin products.

Europe

A steady second market.

Biosimilars

A longer-term growth option.

06What could go wrong

  • FDA inspections. Adverse findings block approvals.
  • Price erosion. US generic prices keep falling.
  • US policy. Tariffs or pricing rules could change economics.

07What the full Aurobindo valuation shows

Model value per share
₹0,000
Upside
+00%
Call
XXXX

Sign in free to see the complete Aurobindo Pharma valuation

  • ✓Fair value per share — from a ten-year discounted cash flow, every step shown
  • ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Aurobindo's value move
  • ✓Bull, base and bear cases — and exactly which assumptions move between them
  • ✓Peer comparison — against Sun Pharma, Dr Reddy's and Lupin
  • ✓Downloadable report — the full write-up, yours to keep
See Aurobindo's fair value and the full DCF — free
Free during launch · unlimited valuations · no card required

08Questions people ask about Aurobindo Pharma

What is Aurobindo Pharma's biggest market?

The US, where it sells a large number of generic medicines.

What is Eugia?

Aurobindo's injectables business.

Why does Aurobindo trade at a low P/E?

Generic drugs face constant price pressure; the DCF tests what that implies.

Is Aurobindo Pharma overvalued?

At ₹1,823 the market is pricing in roughly 5% sustained growth, against the ~8% its own record supports. That is less than it has delivered — on these numbers the market is asking the business for less than its own record, which usually means it doubts the record repeats.

What is the intrinsic value of Aurobindo Pharma?

It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.

How much debt does Aurobindo Pharma carry?

Debt to equity stands at 0.02, against 0.02 at the start of the period — the balance sheet is a core input to the cost of capital used here.

About this research

Written by the FairStocks research team from Aurobindo Pharma's filed accounts and last reviewed 5 Oct 2026; the figures refresh as new results are filed. Every valuation uses the method that fits the business and shows its assumptions — see a fully worked example or the valuation guides. Educational research, not investment advice.

See Aurobindo's fair value and the full DCFUnlock free